SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

The aim of this study is to evaluate the efficacy of SHR-1701 in combination with SBRT in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

Trial Details

NCT ID
NCT07451795
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SHR-1701 + SBRT
  • SBRT
Locations (sample)
  • Fujian, China|28.92651,106.12972
  • Shanghai, China|31.22222,121.45806
  • Xiamen, China|24.47979,118.08187

Key Eligibility Criteria

  • Age: 18 to 80 years old.
  • Diagnosis: Histologically or cytologically confirmed adenocarcinoma of the prostate, clinically staged as metastatic prostate cancer based on conve…
  • Biopsy: Whenever possible, patients should undergo a pre-treatment image-guided biopsy of a lesion; alternatively, archived biopsy tissue obtained …
  • Prior Therapy: Failure of at least one prior next-generation hormone therapy (NHT), such as abiraterone acetate, rezivilutamide, enzalutamide, apal…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →